Compass Therapeutics, Inc. (CMPX) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
CMPX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CMPX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 100.0% | -6661.8% | -5808.8% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CMPX earnings history in CSV or JSON format
Free sign-in required to download data
Compass Therapeutics, Inc. (CMPX) Earnings Overview
As of May 8, 2026, Compass Therapeutics, Inc. (CMPX) reported trailing twelve-month net income of -$68M, reflecting -16.7% year-over-year growth. The company earned $-0.37 per diluted share over the past four quarters.
Looking at the long-term picture, CMPX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$30M in fiscal 2020.
Compass Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), IMVT (-$464M net income), AGEN ($115,000 net income, 0.1% margin), CMPX has comparable earnings metrics. Compare CMPX vs RCUS →
CMPX Earnings vs Peers
Earnings metrics vs comparable public companies
CMPX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$66M | -34.7% | -$73M | $-0.42 | - | - |
| 2024 | -$49M | -16.2% | -$57M | $-0.36 | -5808.8% | -6661.8% |
| 2023 | -$42M | -8.3% | -$50M | $-0.33 | - | - |
| 2022 | -$39M | +52.3% | -$42M | $-0.35 | - | - |
| 2021 | -$82M | -178.6% | -$82M | $-1.31 | - | - |
| 2020 | -$30M | +15.1% | -$28M | $-0.52 | - | - |
| 2019 | -$35M | +9.3% | -$34M | $-0.67 | - | - |
| 2018 | -$38M | - | -$38M | $-7.66 | - | - |
See CMPX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CMPX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CMPX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCMPX — Frequently Asked Questions
Quick answers to the most common questions about buying CMPX stock.
Is CMPX growing earnings?
CMPX EPS fell to $-0.37, with earnings declining -16.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-68M.
What are CMPX's profit margins?
Compass Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CMPX's earnings?
CMPX earnings data spans 2018-2025. The declining earnings trend is -16.7% YoY. Historical data enables comparison across business cycles.